And Then You're Dead

The Permanent Record / Dossier · Health & Medical Records

The Query at the Pharmacy Counter

You hand a prescription across the counter and leave with a paper bag. A copy of the transaction leaves too, for a state database you will probably never see.

When a pharmacy dispenses a controlled substance, it reports the sale to a state prescription drug monitoring program. Prescribers and pharmacists query that database before they write or fill, and every program also answers to law enforcement. In 2017 a federal appeals court held that the DEA could reach Oregon's records with an administrative subpoena, over a state law that demanded a court order. And many states now see the results through a commercial platform that adds an overdose risk score from 0 to 999.

And Then You're Dead · October 2026 · 9 min read

Join the discussion →
Close view of a pharmacy technician's hands sliding white tablets across a teal pill-counting tray with a spatula, the tray's lid tilted open toward the camera
A Navy pharmacy technician counts out tablets for a prescription at the Joint Troop Clinic, Guantanamo Bay, July 23, 2010. The count goes into the bag; the record goes somewhere else. Photo: Joshua Nistas, U.S. Navy, public domain, via Wikimedia Commons (cropped).

Most of the dossiers in this series are assembled by companies, out of records you created without thinking of them as records. This one is assembled by the state, on purpose, and the trigger is a single act: filling a prescription for a controlled substance.

The Centers for Disease Control and Prevention describes a prescription drug monitoring program, a PDMP, in one line: an electronic database that tracks controlled substance prescriptions in a state. Pharmacies submit their dispensing data to it. How quickly varies, the CDC says, from monthly to daily, and some programs run in what it calls real time, meaning under five minutes. By the time you are home with the bag, the sale may already be in the file.

What Goes Into the File

The contents are set by state law, so the clearest way to see them is to read one state's. Oregon's program is run by the Oregon Health Authority and covers drugs in Schedules II through IV of the federal Controlled Substances Act: the opioid painkillers, the stimulants prescribed for attention disorders, the benzodiazepines prescribed for anxiety and sleep, and a long list of others. When an Oregon pharmacy dispenses one of them, it must report electronically, among other things, the patient's name, address, date of birth and sex, the identity of the pharmacy, and the identity of the prescriber.

Put those fields together over time and the file says a good deal more than any one prescription does. It says who your doctors are, which pharmacies you use, what you have been treated with and when, and how often you come back. The Ninth Circuit, describing Oregon's system in 2017, put the volume at roughly 700,000 prescription records uploaded each year.

Oregon's statute calls this information protected health information and says it is not to be disclosed except in limited circumstances. Then it lists the circumstances. Practitioners and pharmacists may get a patient's record when it is for evaluating the need for, or providing, treatment to a patient they are caring for. The list goes on from there: medical examiners, the program's own vendors and contractors, and others. One item on it is law enforcement.

0
federal drug schedules, II through IV, whose dispensing Oregon's program records
0
minutes or less: what the CDC calls real-time reporting, the fastest pace at which some programs receive pharmacy data

Who Asks

The obvious users are the people at the counter and in the exam room. A prescriber looking at a new patient's request for a painkiller can see whether three other doctors have written the same thing this month. A pharmacist can see whether the prescription in front of her is the fourth one filled this week. That is the stated purpose of the whole design, and the CDC lists the PDMP among the most promising state-level interventions for improving opioid prescribing.

The CDC is also candid that the database only helps if someone looks. A provider sees a patient's history only by checking it before prescribing, and some states now require them to check before writing certain controlled substances. State health departments use the data too, to watch the epidemic and to evaluate what is done about it. The evidence on results, the CDC says, is mixed: evaluations show changes in prescribing and some reductions in treatment admissions, not a clean verdict.

And then there is the user the patient is least likely to picture. The Prescription Drug Monitoring Program Training and Technical Assistance Center, a resource center run with support from the Justice Department's Bureau of Justice Assistance, states it flatly: all PDMPs provide access to prescribers, dispensers, regulatory boards and law enforcement. Every one. What varies from state to state is the door law enforcement has to come through.

The database was sold as a tool for the person writing the prescription. Every program in the country also has a door for the person investigating it.

A Court Order, or a Subpoena

Oregon built its door with a lock. The statute lets the health authority disclose a patient's prescription monitoring information to police pursuant to a valid court order based on probable cause, issued at the request of a federal, state or local law enforcement agency engaged in an authorized drug-related investigation involving the person the information is about. Read plainly, an officer who wants your record in Oregon has to convince a judge first.

The federal Drug Enforcement Administration does not usually work that way. Under 21 U.S.C. § 876, the Attorney General, and through delegation the DEA, may issue subpoenas in a drug investigation requiring the production of any records the Attorney General finds relevant or material to the investigation. Those subpoenas, as the Ninth Circuit later put it, are issued without prior approval by a court. The standard is relevance, set by the agency asking. If the recipient refuses, the government can then go to a federal court to enforce the subpoena.

The two systems met in 2012. In January of that year Oregon declined to honor a DEA administrative subpoena for all covered prescriptions written by one physician over about seven months. The DEA went to court, a magistrate judge found Oregon's court-order requirement preempted by federal law, and in August 2012 Oregon produced the records under an order enforcing the subpoena. In September 2012 the DEA issued two more subpoenas to the program, seeking the records of one patient and two prescribing physicians.

This time Oregon sued first. It asked a federal court to declare that it could not be compelled to disclose an individual's health information to the DEA on an administrative subpoena unless a federal court ordered it. The state did not argue that the DEA needed a warrant backed by probable cause. Others did. The ACLU Foundation of Oregon, four patients identified as John Does, and a physician identified as Dr. James Roe intervened, claiming that the DEA's use of subpoenas to get prescription records violated their Fourth Amendment rights. They asked for an order barring the DEA from obtaining PDMP records without a warrant supported by probable cause.

What the Ninth Circuit Decided

The district court in Portland sided with the patients. It held that the DEA's use of administrative subpoenas to obtain PDMP records was a Fourth Amendment violation, and since an unconstitutional federal statute cannot preempt state law, it did not need to reach Oregon's preemption argument. The DEA appealed.

On June 26, 2017, a panel of the Ninth Circuit, Judges M. Margaret McKeown, William A. Fletcher and Raymond C. Fisher, reversed. Its opinion, by Judge McKeown, made two rulings, and neither of them was about whether your prescription history deserves a warrant.

The first ruling was on standing. The patients and the doctor had intervened in Oregon's lawsuit, but they were asking for something Oregon had not asked for: a warrant requirement rather than a court-order requirement. An intervenor who seeks relief different from the party it joins, the court held, must establish its own Article III standing, and these intervenors had not. So the Fourth Amendment claim was out of the case without the court deciding it.

The second ruling was preemption. Oregon by then conceded that the probable-cause part of its statute was preempted by federal law, but argued that the program still had to wait for judicial review and a court order before handing anything over. The court disagreed. Even assuming the probable-cause language could be severed, it held, the court-order requirement stood as an obstacle to the federal scheme, because placing the initial burden of getting a court order on the DEA interferes with the method Congress chose for investigating drug crimes. Section 876 preempted the Oregon statute.

The state wrote a court-order rule. The patients asked for a warrant rule. The court gave the federal agency a subpoena rule, and never said whether the patients were right.

The result is narrower than it sounds and more practical than it looks. The court did not say there is no privacy interest in a PDMP record. It said these intervenors could not raise that question in this posture, and that Oregon could not make the DEA get a judge's order first. The Oregon statute still reads the way it did; for a federal drug investigator in the Ninth Circuit, the lock on the door is now a relevance finding the agency makes for itself.

The Score on Top

There is one more layer between the database and the person reading it. Many states do not present their PDMP data to prescribers and pharmacists raw. They present it through a commercial platform now known as NarxCare, maintained by a company called Bamboo Health.

A 2023 paper in the Journal of the American Medical Informatics Association, by McElfresh, Oliva, Tamang and colleagues, described what that platform shows. NarxCare presents aggregated PDMP data and risk scores based on those data. One of them, the Overdose Risk Score, is a number between 0 and 999 that, in the authors' words, indicates a patient's risk of unintentional overdose death. By their count it was used by 44 of the 54 PDMP programs in the United States.

So the clinician at the terminal is not only reading your list of prescriptions. She may also be reading a three-digit number, computed by a vendor, that claims to say how likely you are to die.

0
the top of the NarxCare Overdose Risk Score scale, which runs from 0
0
of 54 U.S. PDMP programs using NarxCare, by the count in the 2023 JAMIA paper
0
public studies of the score the authors found, each on a small cohort from Ohio, Indiana or Michigan

How Well the Score Has Been Checked

The paper's title is its argument: a call for better validation of opioid overdose risk algorithms. On NarxCare in particular, the authors found three public studies of the score, each using a small cohort of patients from Ohio, Indiana or Michigan. They wrote that the score has never been clinically evaluated, and that there had been no subgroup analysis of it, which is to say no published look at whether it performs differently for different kinds of patients.

They also recorded the worry from practice. Oliva, one of the authors, has warned that using NarxCare and PDMP data can harm patients with complex pain conditions and patients who are uninsured or underinsured. The California Society of Addiction Medicine, they noted, raised concerns about NarxCare's transparency and insufficient validation. On whether the problem is one of tuning, the authors were blunt: they could not determine how, or if, NarxCare can be fixed.

None of that means the score is wrong for any given patient. It means that a number influencing whether a pharmacist fills a prescription, or a doctor writes one, reached most of the country's monitoring programs before the evidence the paper's authors were asking for existed. The patient, in most cases, does not see it at all.

What the Patient Can See

Oregon's statute does require the health authority to keep records of what it discloses: who asked, for what organization, what was released, and when. It requires notice to affected individuals when information is disclosed improperly. It does not, on its face, require that a patient be told when a court order, or after 2017 a federal subpoena, brings law enforcement to their file. The record of the query exists. It is kept by the agency, not sent to you.

And Then You're Dead

Filling a prescription feels like a private exchange between you, your doctor and the person behind the counter. It is also a report to the state, with your name, address, birth date, prescriber and pharmacy attached, into a file that every program in the country makes available to law enforcement. In Oregon the legislature tried to put a judge between that file and the police. The Ninth Circuit held that, for the DEA, federal law moves the judge to the end of the process instead of the beginning, and it disposed of the patients' warrant claim without deciding it. On top of the file, in most states, sits a three-digit number from 0 to 999 about your risk of dying, which researchers writing in 2023 said had never been clinically evaluated. You will not see the query. You will just see the pharmacist look up from the screen.

That's it. That's the whole thing.

Comments

Loading…

Comments are anonymous and moderated.

Sources